Table 2.
Outcomes of extracorporeal membrane oxygenation across study groups.
| Variable | Mortality odds ratio for contrast and 95% credible interval | Posterior probability of increased mortality | Relative explained variation in mortality and 95% credible interval |
|---|---|---|---|
| COVID VV versus pulmonary VV | 2.56 [1.58–4.14] | >99.999% | 13.4% [3.1–23.4] |
| COVID VA versus Cardiac VA | 2.67 [1.1–6.72] | 98.30% | 13.4% [3.1–23.4] |
| Age (61 vs 37) | 3.21 [2.07–5.16] | >99.999% | 24.7% [9.5–35.9] |
| BMI (38 vs 27 kg/m2) | 0.86 [0.6–1.22] | 20.40% | 1.8% [0.2–9.4] |
| Female versus male | 1.78 [1.25–2.44] | >99.999% | 8.9% [0.5–16.3] |
| Mechanical ventilation prior to ECMO (yes vs No) | 0.91 [0.62–1.29] | 30.20% | 0.2% [0–2.9] |
| Anticoagulation (DTI vs heparin) | 1.18 [0.76–1.82] | 76.88% | 0.9% [0–6.1] |
| Anticoagulation (none vs heparin) | 1.41 [0.61–3.15] | 79.33% | 0.9% [0–6.1] |
| Total hours on ECMO (438 vs 41) | 1.03 [0.67–1.59] | 58.23% | 13% [2.9–22.4] |
| Circuit thrombosis (yes vs no) | 1.07 [0.67–1.73] | 60.28% | 0.1% [0–2.7] |
| Oxygenator failure (yes vs No) | 0.91 [0.48–1.75] | 38.25% | 0.1% [0–3.3] |
| Circuit change-out (yes vs no) | 1.07 [0.67–1.68] | 62.33% | 0.1% [0–2.8] |
| Hepatic failure (yes vs no) | 4.38 [2.12–8.47] | >99.999% | 13.7% [3.2–21.1] |
| Renal failure (yes vs No) | 2.98 [1.93–4.48] | >99.999% | 20.1% [5.9–27.9] |
| Time trend (August 21 vs November 20) | 1.15 [0.74–1.77] | 72.38% | 2.5% [0.5–10.8] |
ECMO, extracorporeal membrane oxygenation; VA, venoarterial; VV, venovenous.